Engineers Gate Manager LP Sells 243,693 Shares of uniQure N.V. $QURE

Key Points

• Engineers Gate Manager LP reduced its uniQure stake by 81.3%, selling 243,693 shares and retaining 56,064 shares valued at approximately $2.58 million. Institutional investors collectively own 78.83% of QURE.
• uniQure reported a quarterly loss of $1.22 per share, missing estimates by $0.40, although revenue of $5.84 million exceeded analyst expectations. The company’s negative net margin was 1,350.73%.
• Analyst sentiment remains positive, with a consensus “Moderate Buy” rating and a $65 price target versus the stock’s reported $44.93 price; several firms recently raised their targets as high as $80.

Engineers Gate Manager LP cut its position in uniQure N.V. (NASDAQ:QURE - Free Report) by 81.3% in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 56,064 shares of the biotechnology company's stock after selling 243,693 shares during the quarter. Engineers Gate Manager LP owned 0.08% of uniQure worth $2,582,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently made changes to their positions in QURE. Hennion & Walsh Asset Management Inc. raised its position in uniQure by 107.3% during the second quarter. Hennion & Walsh Asset Management Inc. now owns 142,113 shares of the biotechnology company's stock valued at $6,546,000 after purchasing an additional 73,566 shares in the last quarter. Royal Bank of Canada boosted its holdings in shares of uniQure by 26.0% in the 1st quarter. Royal Bank of Canada now owns 107,888 shares of the biotechnology company's stock valued at $1,763,000 after purchasing an additional 22,248 shares in the last quarter. Kalehua Capital Management LLC bought a new position in shares of uniQure in the 1st quarter valued at $4,760,000. Voss Capital LP increased its stake in shares of uniQure by 68.0% in the 4th quarter. Voss Capital LP now owns 210,000 shares of the biotechnology company's stock valued at $5,025,000 after purchasing an additional 85,000 shares during the last quarter. Finally, Assenagon Asset Management S.A. raised its holdings in shares of uniQure by 249.9% during the 2nd quarter. Assenagon Asset Management S.A. now owns 513,530 shares of the biotechnology company's stock worth $23,653,000 after buying an additional 366,781 shares in the last quarter. Institutional investors own 78.83% of the company's stock.

uniQure Trading Up 0.9%

NASDAQ QURE opened at $44.93 on Tuesday. The company has a quick ratio of 10.01, a current ratio of 10.01 and a debt-to-equity ratio of 0.15. uniQure N.V. has a twelve month low of $8.73 and a twelve month high of $71.50. The company has a market cap of $3.12 billion, a price-to-earnings ratio of -11.20 and a beta of 0.94. The business's fifty day moving average is $44.43 and its 200 day moving average is $31.31.

uniQure (NASDAQ:QURE - Get Free Report) last issued its earnings results on Wednesday, July 29th. The biotechnology company reported ($1.22) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.82) by ($0.40). uniQure had a negative return on equity of 111.96% and a negative net margin of 1,350.73%.The firm had revenue of $5.84 million during the quarter, compared to analyst estimates of $5.45 million. During the same period in the previous year, the company earned ($0.69) EPS. As a group, sell-side analysts expect that uniQure N.V. will post -3.82 EPS for the current fiscal year.

Insider Transactions at uniQure

In related news, insider Walid Abi-Saab sold 30,000 shares of the firm's stock in a transaction that occurred on Tuesday, June 30th. The shares were sold at an average price of $46.42, for a total value of $1,392,600.00. Following the completion of the transaction, the insider owned 148,235 shares in the company, valued at $6,881,068.70. This trade represents a 16.83% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Madhavan Balachandran sold 11,685 shares of the firm's stock in a transaction that occurred on Wednesday, June 17th. The shares were sold at an average price of $45.06, for a total transaction of $526,526.10. Following the completion of the transaction, the director owned 43,254 shares of the company's stock, valued at approximately $1,949,025.24. This trade represents a 21.27% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders sold 332,175 shares of company stock valued at $15,289,008. Company insiders own 4.65% of the company's stock.

Analysts Set New Price Targets

Several brokerages recently weighed in on QURE. Royal Bank Of Canada upped their price objective on uniQure from $35.00 to $65.00 and gave the stock an "outperform" rating in a research report on Thursday, June 18th. The Goldman Sachs Group increased their target price on shares of uniQure from $14.00 to $46.00 and gave the stock a "neutral" rating in a report on Thursday, June 18th. William Blair started coverage on shares of uniQure in a research note on Wednesday, September 2nd. They issued an "outperform" rating on the stock. Wolfe Research raised shares of uniQure from a "peer perform" rating to an "outperform" rating and set a $65.00 price target on the stock in a report on Wednesday, July 29th. Finally, HC Wainwright upped their price objective on shares of uniQure from $50.00 to $80.00 and gave the stock a "buy" rating in a research report on Monday, June 29th. Fourteen analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $65.00.

About uniQure

uniQure N.V. is a biotechnology company focused on developing gene therapies for serious and life-threatening diseases. The company uses adeno-associated virus (AAV) technology to deliver genetic material intended to address the underlying causes of disease, with research activities spanning neurological, neuromuscular, metabolic and cardiovascular conditions.

uniQure's pipeline has included AMT-130, an investigational gene therapy for Huntington's disease, as well as programs targeting other conditions such as amyotrophic lateral sclerosis and Fabry disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.